<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Pharmacol Rev</journal-id>
<journal-id journal-id-type="iso-abbrev">Pharmacol. Rev</journal-id>
<journal-id journal-id-type="hwp">pharmrev</journal-id>
<journal-id journal-id-type="pmc">Pharmacol Rev</journal-id>
<journal-id journal-id-type="publisher-id">PharmRev</journal-id>
<journal-title-group>
<journal-title>Pharmacological Reviews</journal-title>
</journal-title-group>
<issn pub-type="ppub">0031-6997</issn>
<issn pub-type="epub">1521-0081</issn>
<publisher>
<publisher-name>The American Society for Pharmacology and Experimental Therapeutics</publisher-name>
<publisher-loc>Bethesda, MD</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27591044</article-id>
<article-id pub-id-type="pmc">5050440</article-id>
<article-id pub-id-type="publisher-id">PHARMREV_012260</article-id>
<article-id pub-id-type="doi">10.1124/pr.115.012260</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Kinase-dependent Regulation of Monoamine Neurotransmitter Transporters</article-title>
<alt-title alt-title-type="short">Kinase Modulation of Biogenic Amine Transport</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Bermingham</surname>
<given-names>Daniel P.</given-names>
</name>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Blakely</surname>
<given-names>Randy D.</given-names>
</name>
</contrib>
<aff id="aff1">Department of Pharmacology (D.P.B., R.D.B.) and Psychiatry (R.D.B.), Vanderbilt University Medical Center, Nashville, Tennessee; and Department of Biomedical Sciences, Charles E. Schmidt College of Medicine and Brain Institute, Florida Atlantic University, Jupiter, Florida (R.D.B.)</aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="editor">
<name>
<surname>DAWS</surname>
<given-names>LYNETTE C.</given-names>
</name>
<role>ASSOCIATE EDITOR</role>
</contrib>
</contrib-group>
<author-notes>
<corresp id="cor1"><bold>Address correspondence to:</bold> Dr. Randy D. Blakely, <addr-line>Florida Atlantic University Brain Institute, Room 109 MC-17, 5353 Parkside Drive, Jupiter, FL 33458.</addr-line> E-mail: <email>rblakely@health.fau.edu</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>10</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<month>10</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>1</day>
<month>10</month>
<year>2017</year>
</pub-date>
<!-- PMC Release delay is 12 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
<volume>68</volume>
<issue>4</issue>
<fpage>888</fpage>
<lpage>953</lpage>
<permissions>
<copyright-statement>Copyright Â© 2016 by The American Society for Pharmacology and Experimental Therapeutics</copyright-statement>
<copyright-year>2016</copyright-year>
</permissions>
<self-uri xlink:href="pr.115.012260.pdf" xlink:title="pdf" xlink:type="simple"></self-uri>
<abstract>
<p>Modulation of neurotransmission by the monoamines dopamine (DA), norepinephrine (NE), and serotonin (5-HT) is critical for normal nervous system function. Precise temporal and spatial control of this signaling in mediated in large part by the actions of monoamine transporters (DAT, NET, and SERT, respectively). These transporters act to recapture their respective neurotransmitters after release, and disruption of clearance and reuptake has significant effects on physiology and behavior and has been linked to a number of neuropsychiatric disorders. To ensure adequate and dynamic control of these transporters, multiple modes of control have evolved to regulate their activity and trafficking. Central to many of these modes of control are the actions of protein kinases, whose actions can be direct or indirectly mediated by kinase-modulated protein interactions. Here, we summarize the current state of our understanding of how protein kinases regulate monoamine transporters through changes in activity, trafficking, phosphorylation state, and interacting partners. We highlight genetic, biochemical, and pharmacological evidence for kinase-linked control of DAT, NET, and SERT and, where applicable, provide evidence for endogenous activators of these pathways. We hope our discussion can lead to a more nuanced and integrated understanding of how neurotransmitter transporters are controlled and may contribute to disorders that feature perturbed monoamine signaling, with an ultimate goal of developing better therapeutic strategies.</p>
</abstract>
<counts>
<fig-count count="3"></fig-count>
<table-count count="3"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="400"></ref-count>
<page-count count="66"></page-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name> DJS Export </meta-name>
<meta-value>v1</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
</article>
</pmc-articleset>